CDC NEWS


powered by Surfing Waves


Latest News


Why a pioneering plan to distribute COVID vaccines equitably must succeed


13 Jan 2021

COVAX is key to both immunizing the world’s poorest people and ending the pandemic.


Science advisers: publish evidence behind COVID vaccine dosing strategy


12 Jan 2021

Countries that change established coronavirus vaccine schedules must be transparent, both to maintain public trust and so others can benefit from their knowledge.


Beyond Politics — Promoting Covid-19 Vaccination in the United States


06 Jan 2021

The United States has invested more than $10 billion in Operation Warp Speed to fast-track SARS-CoV-2 vaccines from conception to market in 1 year. The result is 11 candidates reaching the final stage of Food and Drug Administration testing — a phenomenal improvement over past development timelines. Indeed, two SARS-CoV-2 vaccines are already available to Americans.


What To Expect Of The COVID-19 Pandemic In 2021: Ask Our Experts


05 Jan 2021

Join our medical expert and wellness editor for a conversation about vaccines, when schools and businesses may reopen, and if life will return to normal.


As Rollout Falters, Scientists Debate New Vaccination Tactics


04 Jan 2021

Should second doses be delayed? Should most adults receive half-doses? Scientists are pondering ways to get more shots into more arms.




Articles


Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study


17 Mar 2021

The vast majority of people who recover from Covid-19 remain protective immunity from the virus for at least six months, researchers reported on Wednesday in a large study from Denmark. The study revealed protective immunity to be approximately 80–83% in people younger than 65 years. We found no difference in immunity over the study period. Among those aged 65 years and older, immunity was estimated to be approximately 47%.




SARS-CoV-2 Vaccines


26 Feb 2021

Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with SARS-CoV-2 revealed that binding and neutralizing antibodies primarily target the receptor-binding domain of the S1 subunit.




SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities


17 Feb 2021

. SARS-CoV-2, like other RNA viruses, constantly changes through mutation, with new variants occurring over time. Generally, when new variants become more common, they do so because of some selective advantage to the virus.




The US Regulatory System and COVID-19 Vaccines The Importance of a Strong and Capable FDA


15 Feb 2021

For many in public health and medicine, the coronavirus disease 2019 (COVID-19) pandemic in the US has been a frustrating journey from one disappointment to the next: late access to testing, insufficient staff and inadequate funding for contact tracing, jumbled communications, and, at the end of 2020, a chaotic launch of vaccination efforts.




COVID-19 Vaccination in Pregnant and Lactating Women


08 Feb 2021

Pregnant women with severe or critical coronavirus disease 2019 (COVID-19) infection are at increased risk for preterm birth and pregnancy loss.




Enroll for Free